MARKET

AEMD

AEMD

Aethlon Medical
NASDAQ
0.6875
+0.0025
+0.37%
After Hours: 0.7400 +0.0525 +7.64% 19:58 07/15 EDT
OPEN
0.6900
PREV CLOSE
0.6850
HIGH
0.7190
LOW
0.6601
VOLUME
95.62K
TURNOVER
--
52 WEEK HIGH
27.40
52 WEEK LOW
0.6400
MARKET CAP
1.81M
P/E (TTM)
-0.0648
1D
5D
1M
3M
1Y
5Y
1D
Patients In Aethlon Medical's Second Cohort Of Its Australian Oncology Feasibility Study Demonstrated Biological Changes
Benzinga · 2d ago
Aethlon Medical announces results from Hemopurifier trial in Australia
TipRanks · 2d ago
Aethlon Medical reports biomarker shifts in second cohort of Hemopurifier cancer trial
PUBT · 2d ago
AETHLON MEDICAL CONTINUES TO OBSERVE DIRECTIONAL CHANGES IN SECOND COHORT OF AUSTRALIAN ONCOLOGY CLINICAL TRIAL EVALUATING HEMOPURIFIER®
Reuters · 2d ago
Weekly Report: what happened at AEMD last week (0706-0710)?
Weekly Report · 2d ago
Aethlon Medical Announces July 2026 Financing Offering
TipRanks · 07/08 10:30
Aethlon Medical prices $4 million offering with warrants exercisable at $0.71 on shareholder approval
PUBT · 07/06 13:28
Aethlon Medical Prices $4M Follow-On Offering Of 5,633,009 Shares And Warrants At $0.7101 Per Unit
Benzinga · 07/06 13:27
More
About AEMD
Aethlon Medical, Inc. is a clinical-stage medical device company. The Company is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy.

Webull offers Aethlon Medical Inc stock information, including NASDAQ: AEMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AEMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AEMD stock methods without spending real money on the virtual paper trading platform.